Thus, since the identification of molecular markers like hENT1 could predict gemcitabine efficacy in leiomyosarcoma and angiosarcoma patients, evaluation of hENT1 expression level would allow a better patient selection with a high possibility to benefit from this chemotherapy regimen. The gene discussed is SLC29A1; the disease is angiosarcoma.